Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congress Instructs FDA On Nanotech Work, But Mum On Regulations

This article was originally published in The Tan Sheet

Executive Summary

The recently passed user fee reauthorization includes a provision that directs FDA to evaluate nano-engineered products’ potential benefits and safety. Friends of the Earth says nanotech products are available “prematurely … without having enough safety data.”

You may also be interested in...



Advocates Push To Ban Anatase Titanium Dioxide Sunscreens

A study found nano-sized particles of sunscreen and UV-absorbing-ingredient anatase TiO2 in brands including L’Oreal, Procter & Gamble’s Cover Girl, Beiersdorf’s Nivea and several smaller brands. The substance garnered attention after 2008 reports that roof coatings broke down in places where workers inadvertently transferred sunscreen via skin contact.

Advocates Push To Ban Anatase Titanium Dioxide Sunscreens

A study found nano-sized particles of sunscreen and UV-absorbing-ingredient anatase TiO2 in brands including L’Oreal, Procter & Gamble’s Cover Girl, Beiersdorf’s Nivea and several smaller brands. The substance garnered attention after 2008 reports that roof coatings broke down in places where workers inadvertently transferred sunscreen via skin contact.

House FDA Appropriations Chairman Has Budget-Cutting History

Alabama Republican Robert Aderholt takes over as House FDA appropriations subcommittee chair, while Maryland Democrat Barbara Mikulski now runs the Senate Appropriations Committee.

Related Content

Topics

UsernamePublicRestriction

Register

PS105867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel